Actinogen Director Geoffrey Brooke Increases Stake via Placement

Actinogen Medical ( (AU:ACW) ) just unveiled an update.

Actinogen Medical has disclosed a change in the interests of director Dr Geoffrey Brooke following the issue of director placement shares. After shareholder approval on 18 March 2026, Brooke acquired 1,357,857 fully paid ordinary shares indirectly for consideration of about $57,030, increasing his total direct and indirect shareholdings and options in the company.

The transaction, executed via a director placement, strengthens Brooke’s equity stake and further ties his financial interests to Actinogen Medical’s performance. This increased alignment between the director and shareholders may be viewed positively by investors monitoring board commitment and capital structure, although the incremental dilution from new shares will factor into overall share capital dynamics.

The most recent analyst rating on (AU:ACW) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Limited is an Australian biotechnology company focused on developing therapies in the medical sector. The company is listed on the ASX and uses a combination of employee share plans, listed options and placements to align directors’ and executives’ interests with shareholders.

Average Trading Volume: 4,677,205

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$125.1M

For an in-depth examination of ACW stock, go to TipRanks’ Overview page.